93 related articles for article (PubMed ID: 6114260)
1. Thromboxane synthase inhibition in patients with atherosclerotic heart disease.
Knudsen JB; Juhl A; Gormsen J
Lancet; 1981 Jul; 2(8239):198. PubMed ID: 6114260
[No Abstract] [Full Text] [Related]
2. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation.
Bartele V; Cerletti C; Schiepatti A; di Minno G; de Gaetano G
Lancet; 1981 May; 1(8228):1057-8. PubMed ID: 6112437
[No Abstract] [Full Text] [Related]
3. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin.
Bertelé V; Falanga A; Roncaglioni MC; Cerletti C; de Gaetano G
Thromb Haemost; 1982 Jun; 47(3):294. PubMed ID: 7051411
[No Abstract] [Full Text] [Related]
4. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor.
Cerletti C; Rajtar G; Bertelé V; de Gaetano G
Thromb Haemost; 1984 Oct; 52(2):215. PubMed ID: 6441306
[No Abstract] [Full Text] [Related]
5. Effects of dazoxiben on transcardiac thromboxane levels and haemodynamics in coronary heart disease.
Hutton I; Tweddel AC; Rankin AC; Walker ID; Davidson JF
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):79S-82S. PubMed ID: 6681709
[TBL] [Abstract][Full Text] [Related]
6. [Antithrombotic agents against platelet aggregation].
Tada M; Kuzuya T; Ohmori M
Nihon Rinsho; 1983 Dec; 41(12):2781-6. PubMed ID: 6687068
[No Abstract] [Full Text] [Related]
7. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
Lancet; 1982 Nov; 2(8308):1156-7. PubMed ID: 6128469
[No Abstract] [Full Text] [Related]
8. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
Varfolomeev SD; Lakin KM; Mevkh AT; Novikova NV; Rukazenkov IuZ
Dokl Akad Nauk SSSR; 1985; 282(1):194-6. PubMed ID: 3928305
[No Abstract] [Full Text] [Related]
9. Biology and biochemistry of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():235-40. PubMed ID: 6221529
[No Abstract] [Full Text] [Related]
10. Influence of a thromboxane synthesis inhibitor on the muscle tissue microcirculation of patients with intermittent claudication.
Ehrly AM
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):117S-118S. PubMed ID: 6681700
[No Abstract] [Full Text] [Related]
11. Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
Shikano M; Ogawa K; Ito T; Chen LS; Ito Y; Imaizumi M; Uno T; Tsutsumi S; Satake T
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():375-7. PubMed ID: 3159226
[No Abstract] [Full Text] [Related]
12. The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs.
Huddleston CB; Lupinetti FM; Laws KH; Collins JC; Clanton JA; Hawiger JJ; Oates JA; Hammon JW
Circ Res; 1983 May; 52(5):608-13. PubMed ID: 6682723
[No Abstract] [Full Text] [Related]
13. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.
Randall MJ; Parry MJ; Hawkeswood E; Cross PE; Dickinson RP
Thromb Res; 1981 Jul 1-15; 23(1-2):145-62. PubMed ID: 6795753
[No Abstract] [Full Text] [Related]
14. Lack of synergism between dazoxiben and dipyridamole following administration to man.
Gresele P; Deckmyn H; Arnout J; Zoja C; Vermylen J
Thromb Res; 1985 Jan; 37(1):231-6. PubMed ID: 3838601
[No Abstract] [Full Text] [Related]
15. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
Schumacher WA; Lucchesi BR
J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
[TBL] [Abstract][Full Text] [Related]
16. Effect of the thromboxane synthetase inhibitor Dazoxiben (UK 37-248) on the metabolism of antipyrine in patients with enhanced platelet aggregation.
Staiger C; Walter E; Wang NS; Schuhmacher E; de Vries J; Weber E
Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):250-3. PubMed ID: 6540249
[TBL] [Abstract][Full Text] [Related]
17. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
FitzGerald GA; Brash AR; Oates JA; Pedersen AK
J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
[TBL] [Abstract][Full Text] [Related]
18. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy?
Gresele P; Van Houtte E; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1984 Dec; 52(3):364. PubMed ID: 6099616
[No Abstract] [Full Text] [Related]
20. Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis.
Fitzgerald DJ; Fragetta J; Fenelon LC; FitzGerald GA
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():496-500. PubMed ID: 2959103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
